[1,2,4]Triazolo[1,5-a]pyrimidine-2-sulfonamide, N-(2,6-difluorophenyl)-5-methyl-

Endpoint summary

Additional information

The toxicokinetics of Flumetsulam were determined in male rats following single oral administration at a low (5 mg/kg) and a high (1000 mg/kg) dose level, and following an intravenous injection at 0.75 mg/kg. The same study included a group of mice which received a single oral dose of 1000 mg/kg. The disposition and metabolism was investigated in a second study, where single and multiple oral doses of 5 mg/kg or a single oral dose of 1000 mg/kg were given to male and female Fisher 344 rats.

Data indicate that oral absorption is rapid although incomplete, accounting to 50-70% of the administered dose. Excretion is also rapid with greater than 90% of administered radioactivity recovered by 48 hours post-dosing. Urine is the main route of elimination (52-73% of administered radioactivity), followed by faeces (19-35% of administered radioactivity). The half-lives for urinary elimination is approximately 5 hours at the low dose (either single or multiple), and approximately 7 hours at the high dose. Flumetsulam does not seem to possess any accumulation potential. There were no apparent differences in the absorption, disposition or metabolism of Flumetsulam based on sex or prior exposure. Metabolism is limited, because Flumetsulam was found unchanged in urine and faeces from treated rats and mice, and 2 minor metabolites (<20% of urinary radioactivity) were noted in mice only.